HeraMED Faces Funding and Deployment Milestones Amid Clinical Validation
HeraMED reports strong Q1 FY25 progress with 4,282 registered users on its HeraCARE platform, a new collaboration with Garmin Health, and advancing commercial deals in the US and Europe. Early clinical data suggests improved maternal outcomes and operational efficiencies.
- 4,282 registered mothers on HeraCARE platform as of March 2025
- Strategic collaboration signed with Garmin Health for smartwatch data integration
- Near completion of second major US commercial agreement in Florida
- Clinical evidence shows reduced preterm births and hospital readmissions
- Cash balance steady at $1.884 million amid ongoing cost management
HeraMED’s Growing User Base and Clinical Impact
HeraMED Limited (ASX:HMD) has reported a productive first quarter of fiscal 2025, with its HeraCARE platform now supporting 4,282 registered expectant mothers, including 386 active users. The platform has amassed over 155,000 clinical-grade maternal vital measurements, forming a robust dataset that is beginning to reveal promising clinical trends. Early analysis indicates HeraCARE’s deployment is contributing to earlier detection of high-risk pregnancy complications such as preeclampsia, alongside reductions in preterm birth rates and hospital readmissions. These outcomes not only improve maternal and fetal health but also enhance operational efficiencies for healthcare providers.
Strategic Partnership with Garmin Health
A key highlight of the quarter was the signing of a collaboration agreement with Garmin Health, which will integrate smartwatch lifestyle and wellness data into the HeraCARE platform. This integration enables expectant mothers to share continuous health metrics, such as heart rate, sleep, and activity levels, with their healthcare teams, enriching the platform’s remote monitoring capabilities. The partnership is expected to expand HeraCARE’s data richness and clinical utility, supporting HeraMED’s long-term strategy to leverage data as a valuable asset in maternal care.
Commercial Expansion in the United States
HeraMED is advancing its commercial footprint in the US, nearing completion of a second commercial agreement with a large Florida-based health system. The ongoing deployment at Broward Health remains central to the company’s growth strategy, with over 511 mothers registered since going live. Integration of HeraCARE into Broward’s EPIC electronic medical record system is underway, which will embed the platform more deeply into clinical workflows and broaden its functionality. Discussions with other major east coast health systems continue, positioning HeraMED well in a market increasingly seeking digital, cost-effective maternal care solutions.
Progress in Europe and Australia
In Europe, HeraMED is preparing for its first pilot project and has identified channel partners to expand HeraCARE and HeraBEAT offerings across new markets. A clinical trial in the Netherlands has been completed, with results pending peer review. In Australia, HeraMED continues to deepen relationships with private clinics such as Simply Women, JOGG, and Melbourne Mothers, which recently launched a hybrid connected care model supported by HeraCARE. These partnerships are helping to validate and refine HeraMED’s care plans and smart messaging bundles.
Financial Position and Operational Efficiency
Financially, HeraMED ended the quarter with $1.884 million in cash, despite no customer receipts during the period. The company continues to implement cost reduction initiatives, including a planned restructure of its research and development team to enhance operational efficiency. Grant applications in Australia and Europe are progressing, with positive early responses suggesting potential non-dilutive funding inflows soon. The company also secured a $43,000 unsecured loan facility to finance insurance premiums, reflecting prudent financial management amid ongoing investment in growth.
Strengthening Leadership and Brand Presence
HeraMED bolstered its advisory board with the appointment of Dr. Sharon R. Howell, a seasoned US healthcare executive with extensive experience in digital health and population health management. This addition is expected to enhance HeraMED’s strategic vision and support its expansion in critical maternal health markets. The company also increased its brand visibility by participating in key industry and investor events across Asia Pacific and Australia, signaling its commitment to stakeholder engagement and market education.
Overall, HeraMED’s Q1 FY25 update reflects a company gaining momentum through strategic partnerships, clinical validation, and geographic expansion, all while maintaining a disciplined approach to cash management.
Bottom Line?
HeraMED’s clinical and commercial strides position it well for scaling digital maternity care, but upcoming grant outcomes and contract finalisations will be key to sustaining momentum.
Questions in the middle?
- When will HeraMED publish peer-reviewed clinical trial results to validate early outcome claims?
- How soon will the second major Florida health system contract be finalised and deployed?
- What is the timeline and likelihood of securing the pending grant funding in Australia and Europe?
